Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107616
Filing Date
2025-08-13
Accepted
2025-08-13 07:01:02
Documents
66
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q grtx-20250630.htm   iXBRL 10-Q 1574251
2 EX-10.1 grtx-ex10_1.htm EX-10.1 18442
3 EX-31.1 grtx-ex31_1.htm EX-31.1 16081
4 EX-31.2 grtx-ex31_2.htm EX-31.2 17636
5 EX-32.1 grtx-ex32_1.htm EX-32.1 9099
6 EX-32.2 grtx-ex32_2.htm EX-32.2 8120
  Complete submission text file 0000950170-25-107616.txt   7121134

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT grtx-20250630.xsd EX-101.SCH 1085424
68 EXTRACTED XBRL INSTANCE DOCUMENT grtx-20250630_htm.xml XML 1202672
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)